Agios Pharmaceuticals, Inc.
AGIO
$27.42
-$0.07-0.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 36.26% | 30.57% | 25.96% | 36.07% | 36.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.26% | 30.57% | 25.96% | 36.07% | 36.79% |
| Cost of Revenue | 13.54% | 5.21% | 3.41% | 2.36% | 2.89% |
| Gross Profit | -10.74% | -2.35% | -0.96% | 0.97% | 0.16% |
| SG&A Expenses | 28.47% | 39.12% | 36.51% | 30.76% | 19.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.31% | 15.13% | 13.02% | 10.50% | 7.70% |
| Operating Income | -16.86% | -13.94% | -12.05% | -8.75% | -5.88% |
| Income Before Tax | -156.38% | 290.26% | 301.42% | 303.92% | 431.22% |
| Income Tax Expenses | -116.71% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -159.51% | 278.14% | 288.87% | 291.35% | 407.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -159.51% | 278.14% | 288.87% | 291.35% | 407.03% |
| EBIT | -16.86% | -13.94% | -12.05% | -8.75% | -5.88% |
| EBITDA | -17.20% | -14.33% | -12.40% | -9.15% | -6.34% |
| EPS Basic | -158.99% | 276.72% | 285.73% | 286.86% | 398.96% |
| Normalized Basic EPS | -11.11% | -6.01% | -5.29% | -3.26% | -2.85% |
| EPS Diluted | -161.24% | 269.94% | 278.75% | 279.89% | 387.77% |
| Normalized Diluted EPS | -11.80% | -5.40% | -4.66% | -2.64% | -2.21% |
| Average Basic Shares Outstanding | 2.03% | 2.01% | 2.05% | 2.08% | 2.00% |
| Average Diluted Shares Outstanding | 1.36% | 2.67% | 2.72% | 2.75% | 2.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |